{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:21:14Z","timestamp":1786296074434,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Longcheng Talents Program","award":["CQ20250032"],"award-info":[{"award-number":["CQ20250032"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272421"],"award-info":[{"award-number":["82272421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Project of Jiangsu Commission of Health","award":["K2024037"],"award-info":[{"award-number":["K2024037"]}]},{"name":"Changzhou\u2019s 14th five-year plan project to train high-level health professionals","award":["2022CZLJ027"],"award-info":[{"award-number":["2022CZLJ027"]}]},{"name":"Open project of Jiangsu Provincial Key Laboratory of Key Laboratory of Laboratory Medicine","award":["JSKLM-Z-2024-001"],"award-info":[{"award-number":["JSKLM-Z-2024-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04202-x","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:06:37Z","timestamp":1773245197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["UBQLN1 Inhibition reduces MASH progression through downregulating SIKE\/p38 MAPK pathway in hepatocyte"],"prefix":"10.1186","volume":"24","author":[{"given":"Yifei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"4202_CR1","doi-asserted-by":"crossref","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends in endocrinology and metabolism: TEM. 2024.","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"4202_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.actbio.2024.06.014","volume":"184","author":"X Qin","year":"2024","unstructured":"Qin X, Liu J. Nanoformulations for the diagnosis and treatment of metabolic Dysfunction-associated steatohepatitis. Acta Biomater. 2024;184:37\u201353.","journal-title":"Acta Biomater"},{"issue":"1","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cmet.2024.10.014","volume":"37","author":"JY Liu","year":"2024","unstructured":"Liu JY, Kuna RS, Pinheiro LV, Nguyen PTT, Welles JE, Drummond JM et al. Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase. Cell Metab. 2024;37(1):239\u2013254.","journal-title":"Cell Metab"},{"issue":"1","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JAD-2007-12108","volume":"12","author":"A Serretti","year":"2007","unstructured":"Serretti A, Olgiati P, De Ronchi D. Genetics of alzheimer\u2019s disease. A rapidly evolving field. J Alzheimer\u2019s Disease: JAD. 2007;12(1):73\u201392.","journal-title":"J Alzheimer\u2019s Disease: JAD"},{"issue":"9","key":"4202_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1080\/15548627.2023.2196876","volume":"19","author":"Y Li","year":"2023","unstructured":"Li Y, Xu J, Chen W, Wang X, Zhao Z, Li Y, et al. Hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic SNARE proteins contributing to septic liver injury. Autophagy. 2023;19(9):2504\u201319.","journal-title":"Autophagy"},{"issue":"1","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, et al. UBQLN1 mediates Sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1\u03b2 in hepatocellular carcinoma. Signal Transduct Target Therapy. 2021;6(1):190.","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"4202_CR7","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1021\/acsnano.2c11965","volume":"17","author":"PHD Nguyen","year":"2023","unstructured":"Nguyen PHD, Jayasinghe MK, Le AH, Peng B, Le MTN. Advances in drug delivery systems based on red blood cells and their Membrane-Derived nanoparticles. ACS Nano. 2023;17(6):5187\u2013210.","journal-title":"ACS Nano"},{"key":"4202_CR8","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.2147\/IJN.S504644","volume":"20","author":"G Della Pelle","year":"2025","unstructured":"Della Pelle G, Markelc B, Bozic T, \u0160ribar J, Krizaj I, Zagar Soderznik K, et al. Red blood cell membrane vesicles for SiRNA delivery: A biocompatible carrier with passive tumor targeting and prolonged plasma residency. Int J Nanomed. 2025;20:3269\u2013301.","journal-title":"Int J Nanomed"},{"issue":"1","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","volume":"9","author":"WM Usman","year":"2018","unstructured":"Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.","journal-title":"Nat Commun"},{"issue":"10","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1681\/ASN.2020111561","volume":"32","author":"TT Tang","year":"2021","unstructured":"Tang TT, Wang B, Li ZL, Wen Y, Feng ST, Wu M, et al. Kim-1 targeted extracellular vesicles: A new therapeutic platform for RNAi to treat AKI. J Am Soc Nephrology: JASN. 2021;32(10):2467\u201383.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"5","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.ymthe.2023.03.036","volume":"31","author":"B Peng","year":"2023","unstructured":"Peng B, Yang Y, Wu Z, Tan R, Pham TT, Yeo EYM, et al. Red blood cell extracellular vesicles deliver therapeutic SiRNAs to skeletal muscles for treatment of cancer cachexia. Mol Ther. 2023;31(5):1418\u201336.","journal-title":"Mol Ther"},{"issue":"2","key":"4202_CR12","doi-asserted-by":"publisher","first-page":"e12030","DOI":"10.1002\/jev2.12030","volume":"10","author":"G Zhang","year":"2020","unstructured":"Zhang G, Huang X, Xiu H, Sun Y, Chen J, Cheng G, et al. Extracellular vesicles: natural liver-accumulating drug delivery vehicles for the treatment of liver diseases. J Extracell Vesicles. 2020;10(2):e12030.","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"4202_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41565-023-01563-4","volume":"19","author":"J Kim","year":"2023","unstructured":"Kim J, Eygeris Y, Ryals RC, Jozi\u0107 A, Sahay G. Strategies for non-viral vectors targeting organs beyond the liver. Nat Nanotechnol. 2023;19(4):428\u2013447.","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"4202_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.tem.2017.10.007","volume":"28","author":"A Lawan","year":"2017","unstructured":"Lawan A, Bennett AM. Mitogen-Activated protein kinase regulation in hepatic metabolism. Trends Endocrinol Metab. 2017;28(12):868\u201378.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"4202_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/hep.30597","volume":"70","author":"Z Huang","year":"2019","unstructured":"Huang Z, Wu LM, Zhang JL, Sabri A, Wang SJ, Qin GJ, et al. Dual specificity phosphatase 12 regulates hepatic lipid metabolism through Inhibition of the lipogenesis and apoptosis Signal-Regulating kinase 1 pathways. Hepatology. 2019;70(4):1099\u2013118.","journal-title":"Hepatology"},{"issue":"3","key":"4202_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.nbd.2012.06.018","volume":"48","author":"P Gonz\u00e1lez-P\u00e9rez","year":"2012","unstructured":"Gonz\u00e1lez-P\u00e9rez P, Lu Y, Chian RJ, Sapp PC, Tanzi RE, Bertram L, et al. Association of UBQLN1 mutation with Brown-Vialetto-Van Laere syndrome but not typical ALS. Neurobiol Dis. 2012;48(3):391\u20138.","journal-title":"Neurobiol Dis"},{"issue":"734","key":"4202_CR17","doi-asserted-by":"publisher","first-page":"eade7347","DOI":"10.1126\/scitranslmed.ade7347","volume":"16","author":"L Bai","year":"2024","unstructured":"Bai L, Qu W, Cheng X, Yang H, Huang YP, Wang Z, et al. Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression. Sci Transl Med. 2024;16(734):eade7347.","journal-title":"Sci Transl Med"},{"issue":"4","key":"4202_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/pharmrev.120.000170","volume":"73","author":"S Mathien","year":"2021","unstructured":"Mathien S, Tesni\u00e8re C, Meloche S. Regulation of Mitogen-Activated protein kinase signaling pathways by the Ubiquitin-Proteasome system and its Pharmacological potential. Pharmacol Rev. 2021;73(4):263\u201396.","journal-title":"Pharmacol Rev"},{"key":"4202_CR19","doi-asserted-by":"crossref","unstructured":"Ni R, Jiang J, Zhao M, Huang S, Huang C. Knockdown of UBQLN1 functions as a strategy to inhibit CRC progression through the ERK-c-Myc pathway. Cancers (Basel). 2023;15(12).","DOI":"10.3390\/cancers15123088"},{"issue":"40","key":"4202_CR20","first-page":"18","volume":"8","author":"C Zhang","year":"2009","unstructured":"Zhang C, Saunders AJ. An emerging role for ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med. 2009;8(40):18\u201322.","journal-title":"Discov Med"},{"issue":"12","key":"4202_CR21","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1016\/j.ymthe.2024.11.002","volume":"32","author":"C Unzu","year":"2024","unstructured":"Unzu C, Fern\u00e1ndez-Barrena MG. Harnessing gene therapy for liver metabolic dysfunction: an innovative approach to MASH treatment. Mol Ther. 2024;32(12):4175\u20134176.","journal-title":"Mol Ther"},{"issue":"4","key":"4202_CR22","doi-asserted-by":"publisher","first-page":"e2402933","DOI":"10.1002\/adhm.202402933","volume":"14","author":"J Fan","year":"2024","unstructured":"Fan J, Xiao Z, Dong Y, Ye F, Qiu Y, Zhang C et al. Nanocarrier-Mediated RNA delivery platform as a frontier strategy for hepatic disease treatment: challenges and opportunities. Adv Healthc Mater. 2024;14(4):e2402933.","journal-title":"Adv Healthc Mater"},{"key":"4202_CR23","doi-asserted-by":"publisher","first-page":"115461","DOI":"10.1016\/j.addr.2024.115461","volume":"215","author":"J Bader","year":"2024","unstructured":"Bader J, Brigger F, Leroux JC. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev. 2024;215:115461","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"4202_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discovery. 2024;23(4):281\u2013300.","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"4202_CR25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ymthe.2025.04.002","volume":"33","author":"A Nunes","year":"2025","unstructured":"Nunes A, Zhang T, Mu X, Robbins PD. Therapeutic application of extracellular vesicles in human diseases. Mol Ther. 2025;33(5):2243\u20132251.","journal-title":"Mol Ther"},{"issue":"5","key":"4202_CR26","doi-asserted-by":"publisher","first-page":"e70076","DOI":"10.1002\/jev2.70076","volume":"14","author":"PW Askenase","year":"2025","unstructured":"Askenase PW. Extracellular vesicle (EV) targeted cells release secondary effector evs: indication of how to account for histocompatibility and disease specificity of EV treatments. J Extracell Vesicles. 2025;14(5):e70076.","journal-title":"J Extracell Vesicles"},{"key":"4202_CR27","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.3390\/ijms23115927","volume":"23","author":"L Yang","year":"2022","unstructured":"Yang L, Huang S, Zhang Z, Liu Z, Zhang L. Roles and applications of red blood Cell-Derived extracellular vesicles in health and diseases. Int J Mol Sci. 2022;23:5927.","journal-title":"Int J Mol Sci"},{"key":"4202_CR28","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.3390\/biomedicines11102798","volume":"11","author":"SR Ma","year":"2023","unstructured":"Ma SR, Xia HF, Gong P, Yu ZL. Red blood Cell-Derived extracellular vesicles: an overview of current research Progress, Challenges, and opportunities. Biomedicines. 2023;11:2798.","journal-title":"Biomedicines"},{"issue":"28","key":"4202_CR29","first-page":"e2302130","volume":"10","author":"M Xu","year":"2023","unstructured":"Xu M, Tan J, Zhu L, Ge C, Zhang Y, Gao F, et al. Palmitoyltransferase ZDHHC3 aggravates nonalcoholic steatohepatitis by targeting S-Palmitoylated IRHOM2. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2023;10(28):e2302130.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"4202_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jare.2022.08.006","volume":"47","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yuan Y, Hu L, Tang J, Meng Z, Dai L, et al. ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2\/ERK signaling pathways. J Adv Res. 2023;47:41\u201356.","journal-title":"J Adv Res"},{"issue":"47","key":"4202_CR31","doi-asserted-by":"publisher","first-page":"55767","DOI":"10.1021\/acsami.1c08044","volume":"13","author":"X Wang","year":"2021","unstructured":"Wang X, Hu S, Li J, Zhu D, Wang Z, Cores J, et al. Extruded mesenchymal stem cell nanovesicles are equally potent to natural extracellular vesicles in cardiac repair. ACS Appl Mater Interfaces. 2021;13(47):55767\u201379.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"4202_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of SiRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341\u20135.","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04202-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:55:30Z","timestamp":1776668130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04202-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving animals were conducted according to the ethical policies and procedures approved by the Jiangsu University ethics committee (Approval no. UJS-IACUC-AP-2020033127). Serum samples were obtained from both control individuals and patients diagnosed with MASH at the Changzhou Third People\u2019s Hospital. The research was carried out in adherence to the ethical guidelines established by the Declaration of Helsinki and obtained approval from Jiangsu University (Reference No. 2012258). This study strictly adhered to ethical guidelines, and all sample collections were conducted following the acquisition of written informed consent from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}